PortfoliosLab logoPortfoliosLab logo
TVTX vs. TGTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TVTX vs. TGTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TVTX achieves a 18.29% return, which is significantly lower than TGTX's 34.55% return. Over the past 10 years, TVTX has underperformed TGTX with an annualized return of 9.84%, while TGTX has yielded a comparatively higher 17.63% annualized return.


TVTX

1D
5.21%
1M
0.65%
YTD
18.29%
6M
29.70%
1Y
193.51%
3Y*
33.38%
5Y*
26.22%
10Y*
9.84%

TGTX

1D
9.47%
1M
12.34%
YTD
34.55%
6M
26.89%
1Y
10.16%
3Y*
14.73%
5Y*
2.66%
10Y*
17.63%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TVTX vs. TGTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
TVTX
Travere Therapeutics, Inc.
18.29%119.35%93.77%-57.25%-32.25%13.89%91.94%-37.25%7.40%11.30%
TGTX
TG Therapeutics, Inc.
34.55%-0.96%76.23%44.38%-37.74%-63.48%368.65%170.73%-50.00%76.34%

Correlation

The correlation between TVTX and TGTX is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.31

Correlation (5Y)
Calculated over the trailing 5-year period

0.38

Correlation (10Y)
Calculated over the trailing 10-year period

0.38

Correlation (All Time)
Calculated using the full available price history since Nov 9, 2012

0.36

Fundamentals

Market Cap

TVTX:

$4.15B

TGTX:

$6.42B

EPS

TVTX:

-$0.49

TGTX:

$2.87

PS Ratio

TVTX:

7.88

TGTX:

9.21

PB Ratio

TVTX:

42.06

TGTX:

11.01

Total Revenue (TTM)

TVTX:

$536.20M

TGTX:

$700.35M

Gross Profit (TTM)

TVTX:

$385.20M

TGTX:

$581.54M

EBITDA (TTM)

TVTX:

$11.15M

TGTX:

$156.88M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TVTX vs. TGTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TVTX
TVTX Risk / Return Rank: 9292
Overall Rank
TVTX Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
TVTX Sortino Ratio Rank: 9393
Sortino Ratio Rank
TVTX Omega Ratio Rank: 9191
Omega Ratio Rank
TVTX Calmar Ratio Rank: 9393
Calmar Ratio Rank
TVTX Martin Ratio Rank: 9191
Martin Ratio Rank

TGTX
TGTX Risk / Return Rank: 4646
Overall Rank
TGTX Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
TGTX Sortino Ratio Rank: 4545
Sortino Ratio Rank
TGTX Omega Ratio Rank: 4545
Omega Ratio Rank
TGTX Calmar Ratio Rank: 4747
Calmar Ratio Rank
TGTX Martin Ratio Rank: 4646
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TVTX vs. TGTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Travere Therapeutics, Inc. (TVTX) and TG Therapeutics, Inc. (TGTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


TVTXTGTXDifference

Sharpe ratio

Return per unit of total volatility

2.72

0.22

+2.50

Sortino ratio

Return per unit of downside risk

3.71

0.67

+3.04

Omega ratio

Gain probability vs. loss probability

1.46

1.08

+0.37

Calmar ratio

Return relative to maximum drawdown

5.82

0.30

+5.52

Martin ratio

Return relative to average drawdown

13.42

0.52

+12.90

TVTX vs. TGTX - Sharpe Ratio Comparison

The current TVTX Sharpe Ratio is 2.72, which is higher than the TGTX Sharpe Ratio of 0.22. The chart below compares the historical Sharpe Ratios of TVTX and TGTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


TVTXTGTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.72

0.22

+2.50

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.40

0.03

+0.37

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.17

0.20

-0.03

Sharpe Ratio (All Time)

Calculated using the full available price history

0.29

-0.05

+0.34

Drawdowns

TVTX vs. TGTX - Drawdown Comparison

The maximum TVTX drawdown since its inception was -85.43%, smaller than the maximum TGTX drawdown of -99.52%. Use the drawdown chart below to compare losses from any high point for TVTX and TGTX.


Loading charts...

Drawdown Indicators


TVTXTGTXDifference

Max Drawdown

Largest peak-to-trough decline

-85.43%

-99.52%

+14.09%

Max Drawdown (1Y)

Largest decline over 1 year

-33.49%

-34.12%

+0.63%

Max Drawdown (3Y)

Largest decline over 3 years

-72.80%

-76.95%

+4.15%

Max Drawdown (5Y)

Largest decline over 5 years

-83.12%

-90.75%

+7.63%

Max Drawdown (10Y)

Largest decline over 10 years

-83.64%

-93.19%

+9.55%

Current Drawdown

Current decline from peak

-5.36%

-82.82%

+77.46%

Average Drawdown

Average peak-to-trough decline

-41.16%

-91.47%

+50.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.50%

19.60%

-5.10%

Volatility

TVTX vs. TGTX - Volatility Comparison

The current volatility for Travere Therapeutics, Inc. (TVTX) is 14.71%, while TG Therapeutics, Inc. (TGTX) has a volatility of 19.58%. This indicates that TVTX experiences smaller price fluctuations and is considered to be less risky than TGTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TVTXTGTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.71%

19.58%

-4.87%

Volatility (6M)

Calculated over the trailing 6-month period

51.99%

33.27%

+18.72%

Volatility (1Y)

Calculated over the trailing 1-year period

71.69%

46.62%

+25.07%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.43%

87.72%

-21.29%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

58.33%

86.87%

-28.54%

Dividends

TVTX vs. TGTX - Dividend Comparison

Neither TVTX nor TGTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

TVTX vs. TGTX - Financials Comparison

This section allows you to compare key financial metrics between Travere Therapeutics, Inc. and TG Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
127.20M
204.92M
(TVTX) Total Revenue
(TGTX) Total Revenue
Values in USD except per share items

TVTX vs. TGTX - Profitability Comparison

The chart below illustrates the profitability comparison between Travere Therapeutics, Inc. and TG Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
83.7%
Portfolio components
TVTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 127.20M. Therefore, the gross margin over that period was 0.0%.

TGTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a gross profit of 171.41M and revenue of 204.92M. Therefore, the gross margin over that period was 83.7%.

TVTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported an operating income of -36.60M and revenue of 127.20M, resulting in an operating margin of -28.8%.

TGTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported an operating income of 34.80M and revenue of 204.92M, resulting in an operating margin of 17.0%.

TVTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Travere Therapeutics, Inc. reported a net income of -37.10M and revenue of 127.20M, resulting in a net margin of -29.2%.

TGTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TG Therapeutics, Inc. reported a net income of 19.78M and revenue of 204.92M, resulting in a net margin of 9.7%.


Frequently Asked Questions


TVTX and TGTX have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TGTX has higher volatility (19.58%) compared to TVTX (14.71%). In terms of maximum drawdown, TVTX dropped -85.43% vs TGTX's -99.52%.

TVTX currently has the higher Sharpe Ratio (2.72 vs 0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TVTX and TGTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer